# Hepatitis B Challenge Dose in Adults (V232-059-10)

> **NCT01251276** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 204 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Modified Process Hepatitis B Vaccine

## Key facts

- **NCT ID:** NCT01251276
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-30
- **Primary completion:** 2011-04-12
- **Final completion:** 2011-04-12
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01251276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01251276, "Hepatitis B Challenge Dose in Adults (V232-059-10)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01251276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*